Orthocell Limited

About Orthocell Limited

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and internationally. The company's principal products include CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. In addition, the company develops Striate+ for use in bone and soft tissue repair; SMRT Graft for use in to augment repair of rotator cuff tendinopathy and tear; and Remplir, a nerve wrap. Orthocell Limited was incorporated in 2006 and is based in Murdoch, Australia.

Orthocell is developing world-leading regenerative medicine products to unlock the power of the human body to heal – restoring mobility, function and performance. Life-Changing ProductsOur products are purpose-built to unlock and support the body’s own repair mechanisms.Products PractitionersWe partner with…


OCC.AX Australia

0.41USD0.005 (-1.22%)

• At close Fri Oct 07 2022

ASX exchange

Sector: Healthcare

Industry: Biotechnology

Location Australia, Murdoch

Grade: AEF

53,584,783 USD
BETA (5y)


for 5 years
for 3 years
for 2 years
for last year
for this year
Orthocell Limited
© 2023 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.